ReviewNPJ precision oncology2025
Immunotherapy in lung cancer brain metastases.
Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs.BMC cancer · 2025Pooled it
- Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies.Cancer science · 2026Review
- The potential utility of in-silico approach in identifying phytochemicals against various targets for the management of lung cancer.Discover oncology · 2026Review
- Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.Future oncology (London, England) · 2026Review
- AI-Powered Lesion-Level Tumor Growth Inhibition Modeling Improves Model Stability and Prognostic Association With PFS.CPT: pharmacometrics & systems pharmacology · 2026Article
- TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases.EBioMedicine · 2026Article
- Diagnostic and Therapeutic Strategies for Brain Metastases from Unknown Primary Tumors: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Adenosine Pathway Activation Defines Genetically Linked Immunosuppressive Subtypes in Solid Tumor Brain Metastases.Cancers · 2026Article
- Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer.Biomedicines · 2026Review
- Therapeutic advances with KRASCancer gene therapy · 2026Review
- Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases.Frontiers in oncology · 2026Article
- T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.Frontiers in immunology · 2026Review
- Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements.MedComm · 2025Review
- Patients' survival outcomes in clinical stage IA lung adenocarcinoma not affected by preoperative staging brain magnetic resonance imaging.Translational lung cancer research · 2025Article
- Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.Frontiers in oncology · 2025Article
- Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BM) occur frequently in lung cancer, particularly in non-small cell lung cancer (NSCLC) patients and remain a significant cause of morbidity and mortality. Standard therapies have limited efficacy due to poor crossing of the blood-brain barrier and the distinct features between BM and the primary tumor. This review explores the immune landscape of brain metastatic disease, emerging immunotherapeutic strategies, and promising biomarkers in NSCLC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.